nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.36485/1561-6274-2024-28-4-22-29QQUYOLnefr-2348Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESОнконефрология. Основные подходы к определению нефротоксичности противоопухолевых препаратовOnconephrology. The main approaches to determining the nephrotoxicity of antitumor drugshttps://orcid.org/0000-0002-2733-4524БатюшинМ. М.BatyushinM. M.

Проф. Батюшин Михаил Михайлович, д-р мед. наук, кафедра внутренних болезней №2

344022, г. Ростов-на-Дону, пер. Нахичеванский, д. 29

Prof. Mikhail M. Batyushin, MD, PhD, DMedSci, Department of Internal Diseases No. 2, Professor

344022 Russia, Rostov-on-Don, lane. Nakhichevan, 29

batjushin-m@rambler.ruhttps://orcid.org/0000-0001-6165-3943ЛевицкаяЕ. С.LevitskayaE. S.

Доц. Левицкая Екатерина Сергеевна, д-р мед. наук, кафедра медицинской реабилитации, спортивной медицины, физического воспитания с курсом медико-социальной экспертизы, заведующая кафедрой

344022, г. Ростов-на-Дону, пер. Нахичеванский, д. 29

Associate professor Ekaterina Sergeevna Levitskaya, MD, PhD, DMedSci, Department of Medical Rehabilitation, Sports Medicine, Physical Education with a course of medical and social expertise, Head of the Department

344022 Russia, Rostov-on-Don, lane. Nakhichevan, 29

es.med@mail.ruhttps://orcid.org/0000-0002-2796-9466КотиеваИ. М.KotievaI. M.

Проф. Котиева Инга Мовлиевна, д-р мед. наук, кафедра патологической физиологии, заведующая кафедрой

344022, г. Ростов-на-Дону, пер. Нахичеванский, д. 29

Inga Movlievna Kotieva, Professor, MD,, Department of Pathological Physiology, Head of the Department

344022 Russia, Rostov-on-Don, lane. Nakhichevan, 29

kotieva_im@rostgmu.ruСафроненкоА. В.SafronenkoA. V.

Проф. Сафроненко Андрей Владимирович, д-р мед. наук, кафедра фармакологии и клинической фармакологии, заведующий кафедрой

344022, г. Ростов-на-Дону, пер. Нахичеванский, д. 29

Andrey Vladimirovich Safronenko, Professor, Department of Pharmacology and Clinical Pharmacology, Head of the Department

344022 Russia, Rostov-on-Don, lane. Nakhichevan, 29

safronenko_av@rostgmu.ruРостовский государственный медицинский университетРоссияRostov State Medical UniversityRussian Federation2024160120252842229Copyright © Батюшин М.М., Левицкая Е.С., Котиева И.М., Сафроненко А.В., 20252025Батюшин М.М., Левицкая Е.С., Котиева И.М., Сафроненко А.В.Batyushin M.M., Levitskaya E.S., Kotieva I.M., Safronenko A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/2348

Статья представляет собой обзор литературы по проблеме нефротоксичности противоопухолевых препаратов. Рассматриваются клинические проявления нефротоксичности, в числе которых: острый/хронический тубулоинтерстициальный нефрит (вследствие инфекции, гиперурикемии, кальциурии, лекарственных воздействий и др.); тромботическая микроангиопатия с поражением почек; острый канальцевый некроз; острый кортикальный некроз; тромбозы почечной артерии и ее ветвей; тромбозы почечной вены, ее ветвей, нижней полой вены; гломерулонефрит (нефритический синдром, нефротический синдром, изолированный мочевой синдром; морфологические паттерны IgA-нефропатии, мембранозной нефропатии, болезни минимальных изменений, фокально-сегментарного гломерулосклероза, С3доминантной нефропатии и др.); гемпигментная нефропатия (следствие острого внутрисосудистого гемолиза, реже –  рабдомиолиза); нефрокальциноз, мочекаменная болезнь; пиелонефрит и др. Приводится классификация противоопухолевых препаратов. Поскольку разные классы препаратов обладают разными механизмами развития нефротоксичности, в статье рассматриваются основные из них с приведением примеров. Также в статье приведены известные и перспективные подходы к профилактике и лечению нефротоксичности противоопухолевых препаратов.

This is a review of the literature on the problem of nephrotoxicity of antitumor drugs. Clinical manifestations of nephrotoxicity are considered, including acute/chronic tubulointerstitial nephritis (due to infection, hyperuricemia, calciuria, drug effects, etc.); thrombotic microangiopathy with kidney damage; acute tubular necrosis; acute cortical necrosis; thrombosis of the renal artery and its branches; thrombosis of the renal vein, its branches, inferior vena cava; glomerulonephritis (nephritic syndrome, nephrotic syndrome, isolated urinary syndrome; morphological patterns of IgA nephropathy, membranous nephropathy, disease of minimal changes, focal segmental glomerulosclerosis, C3 dominant nephropathy, etc.); hempigmental nephropathy (a consequence of acute intravascular hemolysis, less often – rhabdomyolysis); nephrocalcinosis, urolithiasis; pyelonephritis, etc. The classification of antitumor drugs is given. Since different classes of drugs have different mechanisms for the development of nephrotoxicity, the article discusses the main ones with examples. The article also presents well-known and promising approaches to the prevention and treatment of nephrotoxicity of antitumor drugs.

нефротоксичностьпротивоопухолевые препаратыnephrotoxicityantitumor drugsReferencesБурнашева ЕВ, Шатохин ЮВ, Снежко ИВ, Мацуга АА. Поражение почек при противоопухолевой терапии. Нефрология 2018;22(5):17–24. https://doi.org/10.24884/1561-6274-2018-22-5-17-24Burnasheva EV, Shatokhin YV, Snezhko IV, Matsuga AA. Kidney injury in cancer therapy. Nephrology (Saint-Petersburg) 2018;22(5):17–24 (in Russ.).https://doi.org/10.24884/1561-6274-2018-22-5-17-24Zhong L, Li Y, Xiong L et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther 2021;6(1):201. doi: 10.1038/s41392-021-00572-wZhong L, Li Y, Xiong L et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther 2021;6(1):201. doi: 10.1038/s41392-021-00572-wTsao LC, Force J, Hartman ZC. Mechanisms of Therapeutic Antitumor Monoclonal Antibodies. Cancer Res 2021;81(18):4641– 4651. doi: 10.1158/0008-5472.CAN-21-1109Tsao LC, Force J, Hartman ZC. Mechanisms of Therapeutic Antitumor Monoclonal Antibodies. Cancer Res 2021;81(18):4641– 4651. doi: 10.1158/0008-5472.CAN-21-1109Feng H, Fabrizi J, Li J, Mayer C. Syntheses of Polypeptides and Their Biomedical Application for Anti-Tumor Drug Delivery. Int J Mol Sci 2022;23(9):5042. doi: 10.3390/ijms23095042Feng H, Fabrizi J, Li J, Mayer C. Syntheses of Polypeptides and Their Biomedical Application for Anti-Tumor Drug Delivery. Int J Mol Sci 2022;23(9):5042. doi: 10.3390/ijms23095042Nicolò E, Giugliano F, Ascione L et al. Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. Cancer Treat Rev 2022;106:102395. doi: 10.1016/j.ctrv.2022.102395Nicolò E, Giugliano F, Ascione L et al. Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. Cancer Treat Rev 2022;106:102395. doi: 10.1016/j.ctrv.2022.102395Bonilla M, Gudsoorkar P, Wanchoo R et al. Onconephrology 2022: An Update. Kidney360 2023;4(2):258–271. doi: 10.34067/KID.0001582022Bonilla M, Gudsoorkar P, Wanchoo R et al. Onconephrology 2022: An Update. Kidney360 2023;4(2):258–271. doi: 10.34067/KID.0001582022Volarevic V, Djokovic B, Jankovic MG et al. Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity. J Biomed Sci 2019;26(1):25. doi: 10.1186/s12929-019-0518-9Volarevic V, Djokovic B, Jankovic MG et al. Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity. J Biomed Sci 2019;26(1):25. doi: 10.1186/s12929-019-0518-9Sears SM, Siskind LJ. Potential Therapeutic Targets for Cisplatin-Induced Kidney Injury: Lessons from Other Models of AKI and Fibrosis. J Am Soc Nephrol 2021;32(7):1559–1567. doi: 10.1681/ASN.2020101455Sears SM, Siskind LJ. Potential Therapeutic Targets for Cisplatin-Induced Kidney Injury: Lessons from Other Models of AKI and Fibrosis. J Am Soc Nephrol 2021;32(7):1559–1567. doi: 10.1681/ASN.2020101455Hajian S, Rafieian-Kopaei M, Nasri H. Renoprotective effects of antioxidants against cisplatin nephrotoxicity. J Nephropharmacol 2014 Jul 1;3(2):39–42Hajian S, Rafieian-Kopaei M, Nasri H. Renoprotective effects of antioxidants against cisplatin nephrotoxicity. J Nephropharmacol 2014 Jul 1;3(2):39–42Zhang D, Luo G, Jin K et al. The underlying mechanisms of cisplatin-induced nephrotoxicity and its therapeutic intervention using natural compounds. Naunyn Schmiedebergs Arch Pharmacol 2023;396(11):2925–2941. doi: 10.1007/s00210-023-02559-6Zhang D, Luo G, Jin K et al. The underlying mechanisms of cisplatin-induced nephrotoxicity and its therapeutic intervention using natural compounds. Naunyn Schmiedebergs Arch Pharmacol 2023;396(11):2925–2941. doi: 10.1007/s00210-023-02559-6Qi Z, Li W, Tan J et al. Effect of ginsenoside Rh2 on renal apoptosis in cisplatin-induced nephrotoxicity in vivo. Phytomedicine 2019;61:152862. https://doi.org/10.1016/j.phymed.2019.152862Qi Z, Li W, Tan J et al. Effect of ginsenoside Rh2 on renal apoptosis in cisplatin-induced nephrotoxicity in vivo. Phytomedicine 2019;61:152862. https://doi.org/10.1016/j.phymed.2019.152862Wang YM, Wang Y, Harris DC et al. Adriamycin nephropathy in BALB/c mice. Curr Protoc Im 2015;15(28):11–16Wang YM, Wang Y, Harris DC et al. Adriamycin nephropathy in BALB/c mice. Curr Protoc Im 2015;15(28):11–16Yi M, Zhang L, Liu Y, et al. Autophagy is activated to protect against podocyte injury in adriamycin-induced nephropathy. Am J Physiol Ren Physiol 2017;313(1):F74–F84. doi: 10.1152/ajprenal.00114.2017Yi M, Zhang L, Liu Y, et al. Autophagy is activated to protect against podocyte injury in adriamycin-induced nephropathy. Am J Physiol Ren Physiol 2017;313(1):F74–F84. doi: 10.1152/ajprenal.00114.2017Lee VW, Harris DC. Adriamycin nephropathy: a model of focal segmental glomerulosclerosis. Nephrology (Carlton) 2011;16(1):30–38. doi: 10.1111/j.1440-1797.2010.01383.xLee VW, Harris DC. Adriamycin nephropathy: a model of focal segmental glomerulosclerosis. Nephrology (Carlton) 2011;16(1):30–38. doi: 10.1111/j.1440-1797.2010.01383.xSánchez-González PD, López-Hernández FJ, LópezNovoa JM, Morales AI. An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity. Crit Rev Toxicol 2011;41(10):803–821. doi: 10.3109/10408444.2011.602662Sánchez-González PD, López-Hernández FJ, LópezNovoa JM, Morales AI. An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity. Crit Rev Toxicol 2011;41(10):803–821. doi: 10.3109/10408444.2011.602662Tan RZ, Wang C, Deng C et al. Quercetin protects against cisplatin-induced acute kidney injury by inhibiting Mincle/Syk/NFkappaB signaling maintained macrophage inflammation. Phytother Res 2020;34:139–152. https://doi.org/10.1002/ptr.6507Tan RZ, Wang C, Deng C et al. Quercetin protects against cisplatin-induced acute kidney injury by inhibiting Mincle/Syk/NFkappaB signaling maintained macrophage inflammation. Phytother Res 2020;34:139–152. https://doi.org/10.1002/ptr.6507Domitrovic R, Cvijanovic O, Pernjak-Pugel E et al. Berberine exerts nephroprotective effect against cisplatin-induced kidney damage through inhibition of oxidative/nitrosative stress, inflammation, autophagy and apoptosis. Food Chem Toxicol 2013;62:397–406. https://doi.org/10.1016/j.fct.2013.09.003Domitrovic R, Cvijanovic O, Pernjak-Pugel E et al. Berberine exerts nephroprotective effect against cisplatin-induced kidney damage through inhibition of oxidative/nitrosative stress, inflammation, autophagy and apoptosis. Food Chem Toxicol 2013;62:397–406. https://doi.org/10.1016/j.fct.2013.09.003Kumar P, Barua CC, Sulakhiya K et al. Curcumin ameliorates cisplatin-induced nephrotoxicity and potentiates its anticancer activity in SD rats: potential role of curcumin in breast cancer chemotherapy. Front Pharmacol 2017; 8:132. https://doi.org/10.3389/fphar.2017.00132Kumar P, Barua CC, Sulakhiya K et al. Curcumin ameliorates cisplatin-induced nephrotoxicity and potentiates its anticancer activity in SD rats: potential role of curcumin in breast cancer chemotherapy. Front Pharmacol 2017; 8:132. https://doi.org/10.3389/fphar.2017.00132Ali N, AlAsmari AF, Imam F et al. Protective effect of diosmin against doxorubicin-induced nephrotoxicity. Saudi J Biol Sci 2021;28(8):4375–4383. doi: 10.1016/j.sjbs.2021.04.030Ali N, AlAsmari AF, Imam F et al. Protective effect of diosmin against doxorubicin-induced nephrotoxicity. Saudi J Biol Sci 2021;28(8):4375–4383. doi: 10.1016/j.sjbs.2021.04.030Xiang C, Yan Y, Zhang D. Alleviation of the doxorubicininduced nephrotoxicity by fasudil in vivo and in vitro. J Pharmacol Sci 2021;145(1):6–15. doi: 10.1016/j.jphs.2020.10.002Xiang C, Yan Y, Zhang D. Alleviation of the doxorubicininduced nephrotoxicity by fasudil in vivo and in vitro. J Pharmacol Sci 2021;145(1):6–15. doi: 10.1016/j.jphs.2020.10.002Ibrahim Fouad G, Ahmed KA. The protective impact of berberine against doxorubicin-induced nephrotoxicity in rats. Tissue Cell 2021;73:101612. doi: 10.1016/j.tice.2021.101612Ibrahim Fouad G, Ahmed KA. The protective impact of berberine against doxorubicin-induced nephrotoxicity in rats. Tissue Cell 2021;73:101612. doi: 10.1016/j.tice.2021.101612da Silva Faria MC, Santos NA, Carvalho Rodrigues MA et al. Effect of diabetes on biodistribution, nephrotoxicity and antitumor activity of cisplatin in mice. Chem Biol Interact 2015 Mar 5;229:119–131. doi: 10.1016/j.cbi.2015.01.027da Silva Faria MC, Santos NA, Carvalho Rodrigues MA et al. Effect of diabetes on biodistribution, nephrotoxicity and antitumor activity of cisplatin in mice. Chem Biol Interact 2015 Mar 5;229:119–131. doi: 10.1016/j.cbi.2015.01.027Attieh RM, Nunez B, Copeland-Halperin RS, Jhaveri KD. Cardiorenal Impact of Anti-Cancer Agents: The Intersection of Onco-Nephrology and Cardio-Oncology. Cardiorenal Med 2024;14(1):281–293. doi: 10.1159/000539075Attieh RM, Nunez B, Copeland-Halperin RS, Jhaveri KD. Cardiorenal Impact of Anti-Cancer Agents: The Intersection of Onco-Nephrology and Cardio-Oncology. Cardiorenal Med 2024;14(1):281–293. doi: 10.1159/000539075

The authors declare that there are no conflicts of interest present.